EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

KOH 5% solution versus diclofenac 3% for the treatment of actinic keratosis – Results from a three‐armed RCT

U Reinhold iD, N Leitz, R Dominicus, E L Szabó, T Dirschka, G Popp, T C Fischer, N Adamini, R Ostendorf, M Asefi, H Durani, T Hölting und 7 weitere

Journal of the European Academy of Dermatology and Venereology · 2026

DOI: 10.1111/jdv.70069 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2026. Verfasst von U Reinhold und 18 weiteren Autor:innen. Beteiligte Einrichtung: MVZ Dermatologisches Zentrum Bonn GmbH, Bonn, Germany. Hauptthemen laut MEDLINE: Diclofenac, Keratosis, Actinic, Hydroxides, Potassium Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: InfectoPharm Arzneimittel und Consilium GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Actinic Keratosis (AK) has the potential to progress into malignant cancer, thus necessitating timely and effective treatment. Despite several existing therapies, there is still a need for effective, well‐tolerated therapeutic options, especially in the early treatment of patients with few isolated lesions in primary care.

Objectives

To investigate the efficacy and safety of potassium hydroxide (KOH) 5% solution in comparison to diclofenac 3% gel and placebo for the treatment of mild‐to‐moderate AK.

Methods

In this randomized controlled trial, patients with mild or moderate AK applied KOH or placebo solution double‐blinded twice daily for 28 days, followed by a 28‐day off‐treatment phase (1 treatment cycle) for up to three treatment cycles or until treatment success. In a third arm, diclofenac was applied twice daily for 60 days and evaluated investigator‐blinded. The primary endpoint was treatment success, defined as complete clearance (CC) of all initially present AK lesions per patient at the end of treatment (EOT).

Results

In total, 631 patients were enrolled. Treatment success was achieved by 45.2% of patients treated with KOH, compared to 23.8% and 22.9% with diclofenac and placebo, respectively. Similarly, complete remission rates for individual lesions were higher with KOH (65.0%) than with diclofenac (45.9%) or placebo (39.9%). KOH showed a faster onset of action, with higher CC rates already after 1 month compared to diclofenac (16.0% vs. 9.2%) and converging efficacies after 6 months. Most adverse reactions were mild and localized, with comparable tolerability of KOH and diclofenac.

Conclusions

KOH 5% solution proved superior to placebo and, when compared to diclofenac 3% gel, demonstrated significantly higher efficacy at EOT, as well as faster onset of action with comparable long‐term efficacy and tolerability. KOH 5% solution is a valuable addition to the available treatment options for lesion‐directed therapy in patients with mild‐to‐moderate AK. Clinicaltrials.gov Identifier NCT 04552327.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiclofenacKeratosis, ActinicHydroxidesPotassium CompoundsAnti-Inflammatory Agents, Non-SteroidalHumansMaleFemaleDouble-Blind MethodAgedMiddle AgedTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

actinic keratosisdiclofenaclesion‐directed therapypotassium hydroxide

Substanzen

Diclofenacpotassium hydroxideHydroxidesPotassium CompoundsAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • MVZ Dermatologisches Zentrum Bonn GmbH, Bonn, Germany.
  • Hautarztpraxis Dr. Leitz Und Kollegen, Stuttgart, Germany.
  • Hautzentrum Dülmen, ProDerma Studieninstitut, Dülmen, Germany.
  • Hautarztzentrum Hamm, Hamm, Germany.
  • Centroderm GmbH, Wuppertal, Germany.
  • Dermazentrum Augsburg, Augsburg, Germany.

ORCID-Profile: U Reinhold, R Gedschold

Förderung

  • InfectoPharm Arzneimittel und Consilium GmbH

Zitieren

APA

Reinhold, U., Leitz, N., Dominicus, R., Szabó, E. L., Dirschka, T., Popp, G., Fischer, T. C., Adamini, N., Ostendorf, R., Asefi, M., Durani, H., Hölting, T., Amann, U., Kreuziger, F., Assmann, T., Brüning, H., Freitag, L., Hoffmann, K., & Gedschold, R. (2026). KOH 5% solution versus diclofenac 3% for the treatment of actinic keratosis – Results from a three‐armed RCT. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70069

Vancouver

Reinhold U, Leitz N, Dominicus R, Szabó EL, Dirschka T, Popp G, et al. KOH 5% solution versus diclofenac 3% for the treatment of actinic keratosis – Results from a three‐armed RCT. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70069

BibTeX
@article{Reinhold2026,
  author = {Reinhold, U and Leitz, N and Dominicus, R and Szabó, E L and Dirschka, T and Popp, G and Fischer, T C and Adamini, N and Ostendorf, R and Asefi, M and Durani, H and Hölting, T and Amann, U and Kreuziger, F and Assmann, T and Brüning, H and Freitag, L and Hoffmann, K and Gedschold, R},
  title = {KOH 5% solution versus diclofenac 3% for the treatment of actinic keratosis – Results from a three‐armed RCT},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70069}
}
Kostenlos starten →